<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153879</url>
  </required_header>
  <id_info>
    <org_study_id>IISPV-HUSJR-LOWHDL</org_study_id>
    <nct_id>NCT02153879</nct_id>
  </id_info>
  <brief_title>Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment</brief_title>
  <acronym>LOWHDL</acronym>
  <official_title>Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Investigacio Sanitaria Pere Virgili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Investigacio Sanitaria Pere Virgili</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The structural and functional alterations of high density lipoproteins (HDL) levels in type 2
      diabetes (T2D) patients linked to hypertriglyceridemia, hyperglycemia, insulin resistance,
      inflammation and oxidation, play a major role in the increased macrovascular risk in these
      patients. An impaired function of the adipose tissue (AT) in T2D contributes to low HDL
      concentrations.

      Objectives: 1) Quantitative and qualitative characterisation of HDL subclasses by
      ultracentrifugation, proteomic and metabolomic techniques. 2) To study the relationship
      between the HDL subclasses, preβ1 HDL and remnant HDL, and clinical determinants of
      arteriosclerosis. 3) Functional in vitro studies of the HDL subclasses determined in
      Objective 1. 4) To study the role of AT determining the low HDL levels. 5) To study the
      impact of HDL increasing drugs on HDL qualitative changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Groups of subjects: a) Diabetic patients with low HDL; b) Non-diabetic patients with low HDL;
      c) Diabetic patients with normal HDL levels; and d) Non-diabetic patients with normal HDL
      levels. The studies will be performed after washing out lipid lowering drugs. Intima media
      thickness (IMT) will be performed in all groups. Main biochemical techniques will be
      centralised. Isolation and characterisation of HDL subclasses and remnant HDL, as well as a
      determination and preβ1 HDL will be performed. HDL studies examining HDL proteomic and
      metabolomic profiles will be performed. Functional studies will determine the effects on the
      endothelium, inflammation, cholesterol efflux and oxidation according the qualitative
      changes. These HDL measurements will be repeated in group (a), after they are treated with
      fibrates or Niacin. HDL metabolism in adipocytes will be extensively studied, and the
      clinical associations between HDL alterations and plasma AT-derived molecules will be
      examined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL particles size and number assessed by nuclear magnetic resonance (NMR) and reported as nm and micromol/L</measure>
    <time_frame>Two periods of 12 weeks treatment according to crossing over design</time_frame>
    <description>HDL particles were studied by NMR in T2D patients after treatment with fenofibrate or Niacin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A1 (Apo A1), apolipoprotein A2 (Apo A2), paraoxonase (PON) HDL concentration (g/l - mg/l)</measure>
    <time_frame>Two periods of 12 weeks treatment according to crossing over design</time_frame>
    <description>Apoprotein and antioxidant enzymes composition of HDL were also measured</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lecithin-cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activity (AU - pmol/h*μl) and mass (microg/ml)</measure>
    <time_frame>Two periods of 12 weeks treatment according to crossing over design</time_frame>
    <description>LCAT and CETP mass and activities were measured;</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fenofibrate 145 mg/day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niacin plus Laropiprant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niacin 2g/day plus Laropiprant for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>fenofibrate 145/day for 12 weeks</description>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>Secalip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin plus laropiprant</intervention_name>
    <description>Niacin 2 g/day plus Laropiprant for 12 weeks</description>
    <arm_group_label>Niacin plus Laropiprant</arm_group_label>
    <other_name>Tredaptive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patients

          -  Age from 30 years to 70 years

          -  HDL not exceeding 50 mg/dl in men or 60 mg/dl in women

        Exclusion Criteria:

          -  to be a smoker

          -  To be diagnosed with diabetes less than three months before

          -  To have triglyceride levels above 400 mg/dl

          -  Glycated hemoglobin higher than 9%

          -  Albuminuria above 300 mg/mg creatinine

          -  Chronic kidney disease (eFGR &lt;30 ml/min/1.73 m2)

          -  Advanced retinopathy

          -  Neuropathy

          -  Cardiovascular disease in the last three months

          -  Chronic liver insufficiency

          -  Neoplastic disease or any chronic or incapacitating disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Masana, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Institut Investigacio Sanitaria Pere Virgili</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.iispv.cat</url>
    <description>Institut Investigacio Sanitaria Pere Virgili- Pere Virgili Health Research institute</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>June 2, 2014</last_update_submitted>
  <last_update_submitted_qc>June 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Investigacio Sanitaria Pere Virgili</investigator_affiliation>
    <investigator_full_name>LUIS MASANA, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HDL</keyword>
  <keyword>Niacin</keyword>
  <keyword>Fenofibrate</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

